drugset / Trial / NCT04329949
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2021-08-23
- Completion
- 2022-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relacorilant | Small molecule | 25 mg | Oral |
| Subject | Relacorilant | Small molecule | 100 mg | Oral |
| Background | Paclitaxel | Small molecule | — | Intravenous |